This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

EARLY-BIRD PRICING ENDS IN:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Poster Presentation


Global Recognition of your Research
Global Recognition of your Research

Share your company's latest research by presenting a poster at the HYBRID Antibody Engineering & Therapeutics 2021 Conference.  In order to ensure we are able to include yours in the program, we will need your materials no later than midnight, Friday November 12, 2021. 

How to Submit your Abstract
How to Submit your Abstract
  • Register for a virtual experience or in-person pass with a poster presentation space (Register online at www.antibodyeng.com)
  • Submit your poster abstract using this form
SUBMIT POSTER

POSTER TOPICS


  • Engineered Cytokines for Cancer Immunotherapy
  • Targeted Drug Conjugates
  • Vaccines and Antibodies to SARS-CoV-2: Dealing with Antigenic Variation
  • Engineering the Fc Region for Therapeutics
  • Innovative Targets for Antibody-based Therapies
  • Single Domain Antibodies: Repertoire, Engineering and Applications
  • High-Throughput Antibody Discovery and Engineering: Driving Innovation Towards 0-day Discovery
  • Antibody Library Design, Selection and Screening
  • When High Affinity Is Necessary in Antibody Therapeutics
  • Intratumoral Immunotherapy Administration
  • Next Wave of Immuno-oncology Therapeutic Antibodies
  • Advances with CAR-effectors
  • Learnings and Challenges in Immune Cell Recruitment Strategies Using Bispecific Antibodies
  • Progression of Innovative Antibody-based Therapeutics to Clinical Stage
  • Machine Learning for Antibody and Protein Engineering
  • Antibody Repertoires and COVID-19